188 related articles for article (PubMed ID: 38046893)
61. CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity.
de Silva S; Fromm G; Shuptrine CW; Johannes K; Patel A; Yoo KJ; Huang K; Schreiber TH
Cancer Immunol Res; 2020 Feb; 8(2):230-245. PubMed ID: 31852716
[TBL] [Abstract][Full Text] [Related]
62. Localized CD47 blockade enhances immunotherapy for murine melanoma.
Ingram JR; Blomberg OS; Sockolosky JT; Ali L; Schmidt FI; Pishesha N; Espinosa C; Dougan SK; Garcia KC; Ploegh HL; Dougan M
Proc Natl Acad Sci U S A; 2017 Sep; 114(38):10184-10189. PubMed ID: 28874561
[TBL] [Abstract][Full Text] [Related]
63. Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding.
Puro RJ; Bouchlaka MN; Hiebsch RR; Capoccia BJ; Donio MJ; Manning PT; Frazier WA; Karr RW; Pereira DS
Mol Cancer Ther; 2020 Mar; 19(3):835-846. PubMed ID: 31879362
[TBL] [Abstract][Full Text] [Related]
64. Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy.
Chen H; Yang Y; Deng Y; Wei F; Zhao Q; Liu Y; Liu Z; Yu B; Huang Z
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35110357
[TBL] [Abstract][Full Text] [Related]
65. A Novel Blockade CD47 Antibody With Therapeutic Potential for Cancer.
Lin F; Xiong M; Hao W; Song Y; Liu R; Yang Y; Yuan X; Fan D; Zhang Y; Hao M; Ye Z; Lu Y; Zhang Y; Wang J; Xiong D
Front Oncol; 2020; 10():615534. PubMed ID: 33469516
[TBL] [Abstract][Full Text] [Related]
66. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.
Willingham SB; Volkmer JP; Gentles AJ; Sahoo D; Dalerba P; Mitra SS; Wang J; Contreras-Trujillo H; Martin R; Cohen JD; Lovelace P; Scheeren FA; Chao MP; Weiskopf K; Tang C; Volkmer AK; Naik TJ; Storm TA; Mosley AR; Edris B; Schmid SM; Sun CK; Chua MS; Murillo O; Rajendran P; Cha AC; Chin RK; Kim D; Adorno M; Raveh T; Tseng D; Jaiswal S; Enger PØ; Steinberg GK; Li G; So SK; Majeti R; Harsh GR; van de Rijn M; Teng NN; Sunwoo JB; Alizadeh AA; Clarke MF; Weissman IL
Proc Natl Acad Sci U S A; 2012 Apr; 109(17):6662-7. PubMed ID: 22451913
[TBL] [Abstract][Full Text] [Related]
67. Durable antitumor responses to CD47 blockade require adaptive immune stimulation.
Sockolosky JT; Dougan M; Ingram JR; Ho CC; Kauke MJ; Almo SC; Ploegh HL; Garcia KC
Proc Natl Acad Sci U S A; 2016 May; 113(19):E2646-54. PubMed ID: 27091975
[TBL] [Abstract][Full Text] [Related]
68. Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.
Voets E; Paradé M; Lutje Hulsik D; Spijkers S; Janssen W; Rens J; Reinieren-Beeren I; van den Tillaart G; van Duijnhoven S; Driessen L; Habraken M; van Zandvoort P; Kreijtz J; Vink P; van Elsas A; van Eenennaam H
J Immunother Cancer; 2019 Dec; 7(1):340. PubMed ID: 31801627
[TBL] [Abstract][Full Text] [Related]
69. Inhibition of autophagy potentiated the anti-tumor effects of VEGF and CD47 bispecific therapy in glioblastoma.
Zhang X; Wang S; Nan Y; Fan J; Chen W; Luan J; Wang Y; Liang Y; Li S; Tian W; Ju D
Appl Microbiol Biotechnol; 2018 Aug; 102(15):6503-6513. PubMed ID: 29754163
[TBL] [Abstract][Full Text] [Related]
70. SIRPα and PD1 expression on tumor-associated macrophage predict prognosis of intrahepatic cholangiocarcinoma.
Yang H; Yan M; Li W; Xu L
J Transl Med; 2022 Mar; 20(1):140. PubMed ID: 35317832
[TBL] [Abstract][Full Text] [Related]
71. An antitumor peptide RS17-targeted CD47, design, synthesis, and antitumor activity.
Wang X; Wang Y; Hu J; Xu H
Cancer Med; 2021 Mar; 10(6):2125-2136. PubMed ID: 33629544
[TBL] [Abstract][Full Text] [Related]
72. Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis.
Zhang W; Huang Q; Xiao W; Zhao Y; Pi J; Xu H; Zhao H; Xu J; Evans CE; Jin H
Front Immunol; 2020; 11():18. PubMed ID: 32082311
[TBL] [Abstract][Full Text] [Related]
73. Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer.
Zhang X; Wang Y; Fan J; Chen W; Luan J; Mei X; Wang S; Li Y; Ye L; Li S; Tian W; Yin K; Ju D
J Immunother Cancer; 2019 Dec; 7(1):346. PubMed ID: 31829270
[TBL] [Abstract][Full Text] [Related]
74. Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed.
Qu T; Li B; Wang Y
Biomark Res; 2022 Apr; 10(1):20. PubMed ID: 35418166
[TBL] [Abstract][Full Text] [Related]
75. ZBTB28 inhibits breast cancer by activating IFNAR and dual blocking CD24 and CD47 to enhance macrophages phagocytosis.
Li L; Gong Y; Tang J; Yan C; Li L; Peng W; Cheng Z; Yu R; Xiang Q; Deng C; Mu J; Xia J; Luo X; Wu Y; Xiang T
Cell Mol Life Sci; 2022 Jan; 79(2):83. PubMed ID: 35048182
[TBL] [Abstract][Full Text] [Related]
76. CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises.
Tong B; Wang M
Future Oncol; 2018 Sep; 14(21):2179-2188. PubMed ID: 29667847
[TBL] [Abstract][Full Text] [Related]
77. Proinflammatory polarization strongly reduces human macrophage in vitro phagocytosis of tumor cells in response to CD47 blockade.
Antonsen KW; Jensen AG; Carstensen M; Nejsum LN; Sorensen BS; Etzerodt A; Moestrup SK; Møller HJ
Eur J Immunol; 2024 Apr; ():e2350824. PubMed ID: 38593339
[TBL] [Abstract][Full Text] [Related]
78. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
[TBL] [Abstract][Full Text] [Related]
79. The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy.
Li Z; Li Y; Gao J; Fu Y; Hua P; Jing Y; Cai M; Wang H; Tong T
Life Sci; 2021 May; 273():119150. PubMed ID: 33662426
[TBL] [Abstract][Full Text] [Related]
80. BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells.
van Helden MJ; Zwarthoff SA; Arends RJ; Reinieren-Beeren IMJ; Paradé MCBC; Driessen-Engels L; de Laat-Arts K; Damming D; Santegoeds-Lenssen EWH; van Kuppeveld DWJ; Lodewijks I; Olsman H; Matlung HL; Franke K; Mattaar-Hepp E; Stokman MEM; de Wit B; Glaudemans DHRF; van Wijk DEJW; Joosten-Stoffels L; Schouten J; Boersema PJ; van der Vleuten M; Sanderink JWH; Kappers WA; van den Dobbelsteen D; Timmers M; Ubink R; Rouwendal GJA; Verheijden G; van der Lee MMC; Dokter WHA; van den Berg TK
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37068796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]